CD59 Antibody, anti-rat, REAfinity™
Synonyms: CD59a, CD59b, MACIF, MAC-IP, Protectin
RECOMBINANT EXTENDED VALIDATION
Clone:
REA452 | TH9
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD59 Antibody, anti-rat, REAfinity™

Flow cytometry applications
APC
APC-Vio 770
Biotin
PE
PE-Vio 770
Vio Bright FITC
Recommended dilution:
1:10
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-106-861, 130-106-817
Description:
Bone marrow cells from Wistar rats were stained with CD59 antibodies or with the corresponding REA Control antibodies (left image) and analyzed with the MACSQuant® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Application imageView details view details

Application imageView details view details
Extended validation for CD59 Antibody, anti-rat, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA452
TH9
high

Cells were incubated with an excess of purified unconjugated CD59 (REA452) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for CD59. Bone marrow cells from Wistar rats were stained with CD59 antibodies and plotted against the side scatter. As a control, CD59 antibody staining was omitted and cells were measured in the same channel. Flow cytometry analysis was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. The recommended titers of respective antibodies from different suppliers were used.

Fixation data

To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.

No fixation
Extended-Validation detailed information image
Post fixation
Extended-Validation detailed information image

Comparison of staining pattern on non-fixed and fixed cells using CD59 (REA452). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD59 Antibody, anti-rat, REAfinity™
Overview

Clone REA452 recognizes the rat CD59 antigen, a 21 kDa glycosylphosphatidylinositol (GPI) linked cell-surface glycoprotein which is also known as MAC-inhibitory protein (MAC-IP), membrane attack complex inhibition factor (MACIF), or protectin. CD59 is widely distributed, being present on all epithelia, endothelia, and on circulating cells, including erythrocytes, monocytes, and some lymphocytes. It inhibits the lytic activity of complement by binding to C8 and C9, thereby blocking the incorporation of mutiple C9 molecules into the membrane attack complex thus preventing functional pore formation.

Additional information: Clone REA452 displays negligible binding to Fc receptors.

Alternative names

CD59a, CD59b, MACIF, MAC-IP, Protectin

Detailed product information

Technical specifications

Clone
REA452
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody, human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
rat
Antigen
CD59
Molecular mass of antigen [kDa]
9
Distribution of antigen
endothelial cells, epithelial cells, monocytes, lymphocytes
Entrez Gene ID
RRID
AB_2658768, AB_2658769, AB_2658776, AB_2658777, AB_2658770, AB_2658766, AB_2658775, AB_2658774, AB_2658773, AB_2658772, AB_2658771

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD59 Antibody, anti-rat, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for CD59 Antibody, anti-rat, REAfinity™
Publications
  1. Rushmere, N. K. et al. (1997) Expression of rat CD59: functional analysis confirms lack of species selectivity and reveals that glycosylation is not required for function. Immunology 90 (4): 640-646
  2. Mizuno, T. et al. (2011) Specific collaboration between rat membrane complement regulators Crry and CD59 protects peritoneum from damage by autologous complement activation. Nephrol Dial Transplant 26 (6): 1821-1830
  3. Rushmere, N. K. et al. (1994) Molecular cloning of the rat analogue of human CD59: structural comparison with human CD59 and identification of a putative active site. Biochem. J. 304 (Pt 2): 595-601

You have previously chosen International as your location.
What do you want to do?